13.24
price down icon2.22%   -0.30
after-market Handel nachbörslich: 13.24
loading
Schlusskurs vom Vortag:
$13.54
Offen:
$13.45
24-Stunden-Volumen:
1.21M
Relative Volume:
0.86
Marktkapitalisierung:
$1.92B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-4.6456
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
-1.34%
1M Leistung:
-19.76%
6M Leistung:
-47.04%
1J Leistung:
-28.28%
1-Tages-Spanne:
Value
$12.92
$13.45
1-Wochen-Bereich:
Value
$12.86
$13.95
52-Wochen-Spanne:
Value
$10.57
$33.33

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name
Firmenname
Denali Therapeutics Inc
Name
Telefon
(650) 866-8547
Name
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Name
Mitarbeiter
443
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
DNLI's Discussions on Twitter

Vergleichen Sie DNLI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DNLI
Denali Therapeutics Inc
13.24 1.95B 340.81M -419.65M -402.10M -2.85
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Hochstufung Cantor Fitzgerald Neutral → Overweight
2025-03-07 Fortgesetzt Morgan Stanley Overweight
2025-02-11 Eingeleitet Deutsche Bank Buy
2025-01-07 Eingeleitet Robert W. Baird Outperform
2025-01-03 Eingeleitet William Blair Outperform
2024-12-16 Hochstufung Stifel Hold → Buy
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-10-07 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-12-13 Eingeleitet Citigroup Buy
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-09-06 Eingeleitet B. Riley Securities Buy
2023-01-30 Eingeleitet SVB Securities Outperform
2022-12-05 Eingeleitet Cowen Outperform
2022-11-02 Hochstufung BTIG Research Neutral → Buy
2022-11-02 Eingeleitet BofA Securities Buy
2022-06-23 Eingeleitet Berenberg Buy
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-09-21 Eingeleitet Oppenheimer Outperform
2021-09-01 Eingeleitet SMBC Nikko Outperform
2021-05-18 Eingeleitet UBS Buy
2021-02-26 Bestätigt H.C. Wainwright Buy
2021-02-10 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-11-11 Bestätigt H.C. Wainwright Buy
2020-10-16 Herabstufung BTIG Research Buy → Neutral
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-20 Bestätigt H.C. Wainwright Buy
2020-03-13 Hochstufung Evercore ISI In-line → Outperform
2020-02-28 Hochstufung Wedbush Neutral → Outperform
2020-02-24 Eingeleitet Jefferies Buy
2020-02-19 Eingeleitet Stifel Hold
2020-01-27 Hochstufung Goldman Neutral → Buy
2019-09-26 Eingeleitet Wedbush Neutral
2019-09-13 Eingeleitet Nomura Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-06-26 Eingeleitet H.C. Wainwright Buy
2018-11-15 Eingeleitet Cantor Fitzgerald Overweight
2018-11-12 Eingeleitet Janney Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-01-02 Eingeleitet Evercore ISI Outperform
2018-01-02 Eingeleitet Goldman Neutral
2018-01-02 Eingeleitet JP Morgan Overweight
2018-01-02 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten

pulisher
May 27, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK

May 27, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 21, 2025

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com

May 20, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus

May 19, 2025
pulisher
May 13, 2025

Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 11, 2025

Where are the Opportunities in (DNLI) - news.stocktradersdaily.com

May 11, 2025
pulisher
May 08, 2025

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN

May 08, 2025
pulisher
May 08, 2025

Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics shares fall after price target cut to $32 - Investing.com

May 08, 2025
pulisher
May 08, 2025

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks

May 08, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks

May 07, 2025
pulisher
May 07, 2025

Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus

May 07, 2025
pulisher
May 06, 2025

Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025
pulisher
May 06, 2025

Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan

May 06, 2025
pulisher
May 05, 2025

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView

May 05, 2025
pulisher
May 01, 2025

Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus

May 01, 2025
pulisher
Apr 22, 2025

First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq

Apr 22, 2025
pulisher
Apr 15, 2025

(DNLI) Technical Data - news.stocktradersdaily.com

Apr 15, 2025
pulisher
Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail

Apr 10, 2025
pulisher
Apr 07, 2025

Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live

Apr 07, 2025
pulisher
Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia

Apr 05, 2025
pulisher
Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research

Apr 03, 2025
pulisher
Apr 02, 2025

Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

What Happened To Denali Therapeutics Stock Wednesday? - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Sector Update: Health Care - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire

Apr 02, 2025

Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):